Skip to content

Superficial Cervical Plexus Block for IJCL Pain Management

Evaluation of the Efficacy of the Superficial Cervical Plexus Block in Reducing Pain Associated With Internal Jugular Central Lines

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05252832
Enrollment
14
Registered
2022-02-23
Start date
2022-01-15
Completion date
2024-12-31
Last updated
2025-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Superficial Cervical Plexus Block, Pain

Keywords

Superficial Cervical Plexus Block, Pain Management

Brief summary

This is a prospective randomized trial evaluating the effect of SCPB on reported patient pain following IJCL placement as compared to local infiltrate.

Detailed description

The goal of this study is to determine if SCPBs provide more pain control than local infiltrate of anesthetic for internal jugular venous cannulation. The investigators hypothesis that patients who receive the SCPB will have a lower VAS rating on average than those who receive local infiltration following internal jugular venous cannulation. To test this, the investigators will be approaching eligible patients for inclusion in a research study. If the patients consent, the patients will be randomly assigned the standard of care treatment or the SCPB. The investigators will then ask the patients to rate pain following insertion of the central line. The investigators will also evaluate different aspects of the patient's hospital course to evaluate their outcomes.

Interventions

Location of injection for block.

PROCEDURELocal Infiltrate

Local infiltration location.

Sponsors

Cleveland Clinic Akron General
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

Participants will be masked to the anesthesia route selected until after they report their pain scale report. Care provider cannot be blinded in order to complete.

Intervention model description

Participant blinded block randomization of the control local infitrate (Arm 1) and the experimental SCPB (Arm 2).

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients who are 18 years and older, and; * Present to the Akron General Emergency Department (Main) between March 1, 2021 and December 1, 2022, and; * Require IJVC as a part of their clinical care.

Exclusion criteria

* Patients who are intubated; or * Patients who undergo CPR; or * Patients who have an allergy to lidocaine or bupivacaine; or * Patients who have a contraindication to receiving a superficial cervical plexus block such as cellulitis over Erb's point or the internal jugular vein, abnormal anatomy, or prior surgery to the area.

Design outcomes

Primary

MeasureTime frameDescription
Visual Analog Scale Rating30 minutes post central line placementThe average Visual Analog Scale (VAS) rating in patients who receive the SCPB during internal jugular venous cannulation versus the average VAS in patients receiving local infiltration. The scale is from 0-10, with 0 meaning no pain and 10 meaning the most pain I have ever experienced.

Secondary

MeasureTime frameDescription
ComplicationsDuration of emergency department and inpatient encounter, typically no more than 7 days.To determine if SCPBs are associated with higher complication rates than local infiltration with internal jugular venous cannulation. Complications will be defined as arterial injury, lacerations of the vena cava, mediastinal vessels, and right atrium, hematoma formation, retained guide wire, pulmonary complications including pneumothorax, pneumomediastinum, chylothorax, tracheal injury, injury to the recurrent laryngeal nerve, and air embolus, tracheal injury, arrhythmia, cardiac arrest, device dysfunction, device infection, and venous thrombosis.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026